Ingenia Therapeutics

CompanyUnited StatesFounded 2018

Ingenia Therapeutics develops one asset, in phase 1 (IGT-303 in chronic kidney disease). Mostly antibody; based in the United States, founded in 2018.

1
Asset
Furthest stage
Phase 1
1
Trial
1
Signal

Pipeline

1
  • IGT-303

    Phase 1, Antibody, chronic kidney disease

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Trials1
  • Signals2
  • Similar companies6

Intelligence